New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
18:29 EDTCALL, MM, SMG, HALO, TRAK, SFM, HEAR, NUAN, CEMP, GSAT, GERN, MTZ, GALE, ICPT, DSTIOn The Fly: After Hours Movers
UP AFTER EARNINGS: DealerTrack (TRAK), up 11.3%... DTS Inc. (DSTI), up 12.8%... Globalstar (GSAT), up 1.6%... Halozyme Therapeutics (HALO), up 2.4%. ALSO HIGHER: Intercept Pharmaceuticals (ICPT), up 57.7% after announcing that 46% of OCA group met FLINT endpoint as well as reporting second quarter results... Cempra (CEMP), up 5.8% following Intercept Pharmaceuticals' FLINT announcement... Scotts Miracle-Gro (SMG), up 3.6% after board approves a $500M share repurchase authorization and announces a $2.00 per share special dividend. DOWN AFTER EARNINGS: Galena Biopharma (GALE), down 13.4%... Nuance Communications (NUAN), down 9.7%... Millennial Media (MM), down 7.1%... MasTec (MTZ), down 3.6%... Turtle Beach (HEAR), down 3.5%... magicJack (CALL), down 5.8%... Geron (GERN), down 2.4%. ALSO LOWER: Sprouts Farmers Market (SFM), down 3.7% after filing to sell 15M shares of common stock for holders.
News For TRAK;DSTI;GSAT;HALO;ICPT;CEMP;SMG;GALE;NUAN;MM;MTZ;HEAR;CALL;GERN;SFM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 17, 2014
07:05 EDTMTZMasTec backs previously issued Q4 guidance
Subscribe for More Information
07:03 EDTMTZMasTec lowers FY15 adjusted EPS view to $1.87 from $2.00-$2.15
Subscribe for More Information
December 16, 2014
09:16 EDTGERNOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTMTZMasTec recent weakness overdone, says FBR Capital
FBR Capital said the recent weakness in shares of MasTec overdone and the firm raised its price target on the stock to $39 from $35 following meetings with management that highlighted its opportunities and addressed concerns. The firm maintains its Outperform rating on MasTec.
07:20 EDTGERNGeron announces early HSR clearance for collaboration with Janssen
Subscribe for More Information
December 15, 2014
16:39 EDTMMMillennial Media files to sell 579,703 shares of common stock
Issuable upon exercise of options assumed as part of the acquisition of Nexage, Inc. The exercise prices of these options are between 7c-24c per share. If all of these options were to be exercised in full, the company would receive total cash proceeds of approximately $82,285.
16:37 EDTMMMillennial Media files to sell 30.73M shares of common stock for holders
Subscribe for More Information
08:58 EDTICPTIntercept reinstated with a Buy at BofA/Merrill
Subscribe for More Information
08:22 EDTMTZMasTec price target lowered to $25.50 from $34.50 at Stifel
Stifel cut its price target on MasTec after the firm cut its estimate for the company to reflect the headwinds from lower oil prices and a more challenging AT&T wireless capex environment. However, the firm thinks the 21% decline in the stock since December 5 was overdone. It keeps a Buy rating on the shares.
December 12, 2014
14:24 EDTNUANNuance management to meet with Wedbush
Subscribe for More Information
December 11, 2014
08:57 EDTICPTLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:40 EDTGALEGalena presents HER2 screening data results from NeuVax Phase 3 clinical trial
Galena Biopharma announced that initial immunohistochemistry, or IHC, screening data from the NeuVax Phase 3 PRESENT, or Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment, trial was presented at the 2014 San Antonio Breast Cancer Symposium, or SABCS. The poster, entitled, "HER2 Discordant Results in Local vs. Central Testing in the Phase 3 Nelipepimut-S Trial and Implementation of Leica Bond Oracle HER2 Immunohistochemistry System for Low and Intermediate Levels of HER2 Protein Expression as a Companion Diagnostic," demonstrated that with the implementation of the Leica Bond Oracle HER2 IHC assay, preliminary limited data indicated additional patients met HER2 eligibility for PRESENT and the assay identified more precisely patients at HER2 1+ and 2+. As part of the PRESENT trial, Galena has implemented central laboratory testing for all potential patients to confirm validated and robust entry criteria, and ensure the enrollment of the targeted patient population. To improve accuracy and specificity for the HER2 1+ and 2+ status testing, and develop a companion diagnostic for NeuVax, the Leica Bond Oracle HER2 IHC system has been incorporated as central HER2 IHC screening for the PRESENT study.
07:51 EDTSMGScotts Miracle-Gro coverage transferred with a Market Perform at Raymond James
Subscribe for More Information
December 10, 2014
08:18 EDTSFMDeutsche Bank to hold a conference
Subscribe for More Information
December 9, 2014
07:41 EDTTRAKBarclays to hold a conference
Global Technology Conference is being held in San Francisco on December 9-10 with webcasted company presentations to begin on December 9 at 10:40 am; not all company presentations may be webcasted. Webcast Link
December 8, 2014
16:24 EDTCEMPOn The Fly: Closing Wrap
Stocks on Wall Street were lower amid another drop in crude oil prices, which tumbled to five-year lows. The market opened slightly lower following weaker than expected data from China and Japan, with nothing of note on the domestic calendar to get buyers involved in the day’s activity. Near noon, the averages gained downside momentum and though the market pared its losses several times, it was never able to gain any steam to pull the indexes back into the green. ECONOMIC EVENTS: In the U.S., no major economic data was released. In Asia, Chinese exports rose 4.7% from a year earlier in November, which missed the consensus estimate for an 8% increase. Chinese imports fell 6.7% from the prior year last month, compared with projections for a 3.8% increase. Additionally, Japan's revised third quarter gross domestic product estimate showed the economy shrank more than initially thought, with growth contracting an annualized 1.9%. COMPANY NEWS: Shares of Cubist Pharmaceuticals (CBST) surged $26.24, or 35.29%, to $100.60 after Merck (MRK) agreed to acquire the maker of next-generation antibiotics for $102 per share in cash, or $8.4B and the assumption of $1.1B in debt. A number of other antibiotic makers also climbed, including Tetraphase (TTPH), which rose $2.45, or 8.82%, to $30.24, and Cempra (CEMP), which advanced $1.64, or 11.37%, to $16.06, while shares of Merck finished fractionally higher, adding 39c, or 0.63%, to $61.88 following the deal announcement. MAJOR MOVERS: Among the notable gainers following their presentations at the American Society of Hematology, or ASH, annual meeting were Calithera Biosciences (CALA), which gained $2.38, or 22.52%, to $12.95, and Acceleron Pharma (XLRN), which jumped $5.11, or 13.6%, to $42.67. Among the noteworthy losers was McDonald's (MCD), which fell $3.70, or 3.84%, to $92.61 after the Dow member reported a 2.2% decline in global same-restaurant sales in November. Additionally, the fast-food giant warned that its fourth quarter results would be hurt by its sales pressures, supplier issues in China and a stronger U.S. dollar. Also lower were shares of Liquidity Services (LQDT), which plunged $2.77, or 27.0%, to $7.49 after the company disclosed that Wal-Mart (WMT) had terminated a deal to provide it with surplus merchandise. INDEXES: The Dow fell 106.31, or 0.59%, to 17,852.48, the Nasdaq dropped 40.06, or 0.84%, to 4,740.69, and the S&P 500 slipped 15.06, or 0.73%, to 2,060.31.
12:25 EDTCEMPAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
09:20 EDTGALEOn The Fly: Pre-market Movers
Subscribe for More Information
08:11 EDTGERNGeron to host analyst and investor meeting
Subscribe for More Information
07:08 EDTGALEGalena GALE-401 Phase 1 results show reduced platelet counts, tolerable safety
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use